Latest Licensing News

Hastings Technology Metals secures 49% of a Thai hydromet plant, aiming for Q4 2026 production using African monazite feedstock, setting a path for early cash flow ahead of Yangibana.

RocketBoots has secured a significant A$3.3 million activation contract with a tier-one multinational retailer and reported over 50% growth in its early sales pipeline, supported by a strong cash position of A$5 million.

Frontier Energy has appointed Jamie Cullen as Executive Chair and is closing in on binding senior debt terms to fund its Waroona Renewable Energy Project, while finalising contracts with tier one suppliers and divesting a non-core asset.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

Kore Potash made steady progress on its Kola Potash Project in Q1 2026, completing key marine and topographic studies while navigating design revisions and ongoing financing talks. The company’s formal sale process continues with one bidder remaining active and cash reserves at US$8.3 million.

Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.

archTIS delivered a 231% year-on-year increase in annual recurring revenue to A$15.1 million, marked by the full deployment of its US Department of Defense custom software and a significant contract with a US-European military alliance.

Terra Critical Minerals has established a US foothold with the True American Tungsten Project acquisition while progressing key Australian and Canadian critical metals projects, positioning for upcoming drilling campaigns.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Marquee Resources has significantly increased its Mt Clement inferred antimony resource and is advancing drilling and strategic partnerships to develop its flagship project.

OpenLearning accelerated its SaaS annual recurring revenue by 35% year-on-year to $3.192 million in Q1 FY26, propelled by larger multi-year LMS contracts and ongoing AI platform enhancements.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.